US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Septerna, Inc.

40.00

-0.7900-1.94%

Post-market: 40.000.00000.00%19:30 EDT

Volume:289.81K

Turnover:11.73M

Market Cap:1.87B

PE:-73.74

High:41.44

Open:41.44

Low:39.95

Close:40.79

52wk High:51.10

52wk Low:11.70

Shares:46.68M

Float Shares:22.90M

Volume Ratio:0.66

T/O Rate:1.27%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.5424

EPS(LYR):-1.1044

ROE:-6.34%

ROA:-7.13%

PB:4.83

PE(LYR):-36.22

Loading ...

Overview Company News Filings

Biotech firm Septerna beats Q4 revenue expectations, net loss narrows

Earnings Flash (SEPN) Septerna Posts Q4 Loss $-0.24, vs. FactSet Est of Loss of $-0.24

MT Newswires Live

Septerna Q4 EPS $(0.24) Misses $0.03 Estimate, Sales $24.118M Miss $32.667M Estimate

Benzinga Earnings

Septerna Q4 revenue hits USD 24.12 million as net loss narrows 48% to USD 10.74 million

Septerna Inc Q4 Income From Operations USD -16.023 Million

THOMSON REUTERS

Press Release: Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Septerna Chief People Officer Samira Shaikhly Disposes of Common Shares

Septerna Is Maintained at Overweight by Wells Fargo

Septerna (SEPN): Early Proof-of-Concept for SEP-631 in Mast Cell–Driven Disease Supports Long-Term Growth Potential

Wells Fargo Sticks to Its Buy Rating for Septerna, Inc. (SEPN)

Septerna Is Maintained at Buy by HC Wainwright & Co.

A Look At Septerna (SEPN) Valuation After Recent Share Price Momentum And GPCR Pipeline Reassessment

Simply Wall St.

Septerna price target raised to $40 from $35 at H.C. Wainwright

Septerna, Inc. : H.c. Wainwright Raises Target Price to $40 From $35

THOMSON REUTERS

Septerna announces results from Phase 1 trial of SEP-631

BRIEF-Septerna Says SEP-631 Well-Tolerated With Adverse Event Profile Comparable To Placebo

Septerna Reports Positive Phase 1 Data for SEP-631 in Mast Cell-Driven Diseases

Septerna Inc - Phase 2 Development for Chronic Spontaneous Urticaria Planned for 2026

THOMSON REUTERS

Septerna Announces Positive Phase 1 Data for SEP-631, an Oral Mrgprx2 Nam for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

THOMSON REUTERS

Septerna Inc - SEP-631 Well-Tolerated With Adverse Event Profile Comparable to Placebo

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/SEPN/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SEPN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SEPN\",,,,,undefined,":{"symbol":"SEPN","market":"US","secType":"STK","nameCN":"Septerna, Inc.","latestPrice":40,"timestamp":1787342400000,"preClose":40.79,"halted":0,"volume":289809,"hourTrading":{"tag":"盘后","latestPrice":40,"preClose":40,"latestTime":"19:30 EDT","volume":5468,"amount":218723.95,"timestamp":1787355006445,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.019367492032360854,"floatShares":22896300,"shares":46676947,"eps":-0.542426,"marketStatus":"Not Yet Opened","change":-0.79,"latestTime":"08-21 16:00:00 EDT","open":41.44,"high":41.44,"low":39.95,"amount":11728973.064509999,"amplitude":0.036529,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.542426,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":0,"adr":0,"listingDate":1729828800000,"exchange":"NASDAQ","adjPreClose":40.79,"preHourTrading":{"tag":"盘前","latestPrice":41.14,"preClose":40.79,"latestTime":"09:11 EDT","volume":114,"amount":4657.219884,"timestamp":1787317879915,"change":0.35,"changeRate":0.008581,"amplitude":0.039716},"postHourTrading":{"tag":"盘后","latestPrice":40,"preClose":40,"latestTime":"19:30 EDT","volume":5468,"amount":218723.95,"timestamp":1787355006445,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6555406165436688,"impliedVol":0.6382,"impliedVolPercentile":0.1952},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SEPN\",,,,,undefined,":{"symbol":"SEPN","floatShares":22896300,"roa":"-7.13%","roe":"-6.34%","lyrEps":-1.104402,"volumeRatio":0.6555406165436688,"shares":46676947,"dividePrice":0,"high":41.44,"amplitude":0.036529,"preClose":40.79,"low":39.95,"week52Low":11.7,"pbRate":"4.83","psRate":"18.88","week52High":51.1,"institutionHeld":0,"latestPrice":40,"eps":-0.542426,"divideRate":0,"volume":289809,"delay":0,"ttmEps":-0.542426,"open":41.44,"prevYearClose":27.88,"prevWeekClose":44.5,"prevMonthClose":34.45,"prevQuarterClose":33.49,"fiveDayClose":44.5,"twentyDayClose":33.1,"sixtyDayClose":29.79},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SEPN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-10","symbol":"SEPN","fiscalQuarterEnding":"2026/06","expectedEps":-0.48,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786334400000,"reportTimeType":"post","actualEps":-0.29},{"market":"US","date":"2026-05-11","symbol":"SEPN","fiscalQuarterEnding":"2026/03","expectedEps":-0.51,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-0.19},{"market":"US","date":"2026-03-09","symbol":"SEPN","fiscalQuarterEnding":"2025/12","expectedEps":-0.23,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773028800000,"reportTimeType":"post","actualEps":-0.24},{"market":"US","date":"2025-11-10","symbol":"SEPN","fiscalQuarterEnding":"2025/09","expectedEps":0.19,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.09},{"market":"US","date":"2025-08-11","symbol":"SEPN","fiscalQuarterEnding":"2025/06","expectedEps":-0.05,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":-0.56}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SEPN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SEPN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3,"buy":0.7,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7,"analysts":10,"updateTime":1781236800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SEPN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SEPN","date":"2026-08-21","current":-73.742778,"percent":0.015453,"low":-92.81078,"twenty":-41.886226,"median":-19.559064,"eighty":-6.073792,"high":261.261398,"avg":-14.222505,"sd":53.336004,"marketCap":1903952668},"quantilePoints":[{"date":"2024-10-25","current":180.873276,"twenty":180.873276,"median":180.873276,"eighty":180.873276,"marketCap":756050292},{"date":"2024-10-31","current":204.688257,"twenty":197.111676,"median":204.688257,"eighty":209.813,"marketCap":855596913},{"date":"2024-11-08","current":261.261398,"twenty":203.984861,"median":216.997688,"eighty":242.57116,"marketCap":1092072644},{"date":"2024-11-15","current":224.885772,"twenty":207.743006,"median":230.613426,"eighty":256.156752,"marketCap":940022529},{"date":"2024-11-22","current":-56.371082,"twenty":203.984861,"median":228.503238,"eighty":245.706296,"marketCap":915240881},{"date":"2024-11-29","current":-69.163916,"twenty":-57.105794,"median":221.92146,"eighty":240.581553,"marketCap":1122945345},{"date":"2024-12-06","current":-68.890433,"twenty":-66.926823,"median":208.506693,"eighty":237.707678,"marketCap":1118505070},{"date":"2024-12-13","current":-61.725172,"twenty":-67.501138,"median":191.022276,"eighty":236.763117,"marketCap":1002169886},{"date":"2024-12-20","current":-63.995083,"twenty":-66.784612,"median":-58.207863,"eighty":234.592638,"marketCap":1039024162},{"date":"2024-12-27","current":-70.449288,"twenty":-68.420042,"median":-60.166317,"eighty":232.180994,"marketCap":1143814633},{"date":"2025-01-03","current":-58.388676,"twenty":-68.655237,"median":-61.232902,"eighty":229.769351,"marketCap":947998541},{"date":"2025-01-10","current":-57.02126,"twenty":-67.714455,"median":-60.412452,"eighty":226.39305,"marketCap":925797170},{"date":"2025-01-17","current":-46.437457,"twenty":-67.358927,"median":-58.853597,"eighty":224.885772,"marketCap":753958559},{"date":"2025-01-24","current":-50.266223,"twenty":-66.593173,"median":-57.614562,"eighty":220.142874,"marketCap":816122397},{"date":"2025-01-31","current":-48.433885,"twenty":-66.401735,"median":-55.982023,"eighty":215.822012,"marketCap":786372560},{"date":"2025-02-07","current":-38.861971,"twenty":-65.110894,"median":-50.840537,"eighty":209.813,"marketCap":630962963},{"date":"2025-02-14","current":-31.587316,"twenty":-64.153703,"median":-49.199638,"eighty":205.451944,"marketCap":512851670},{"date":"2025-02-21","current":-16.108164,"twenty":-63.748948,"median":-46.492154,"eighty":202.578068,"marketCap":261532150},{"date":"2025-02-28","current":-15.862029,"twenty":-63.55204,"median":-46.410109,"eighty":188.992476,"marketCap":257535903},{"date":"2025-03-07","current":-17.393535,"twenty":-63.169163,"median":-46.191322,"eighty":63.291545,"marketCap":282401439},{"date":"2025-03-14","current":-17.47558,"twenty":-62.928498,"median":-43.237703,"eighty":-15.145503,"marketCap":283733521},{"date":"2025-03-21","current":-16.81922,"twenty":-62.747999,"median":-39.764466,"eighty":-15.424456,"marketCap":273076863},{"date":"2025-03-28","current":-3.893469,"twenty":-62.08617,"median":-37.439858,"eighty":-15.424456,"marketCap":279543299},{"date":"2025-04-04","current":-3.590162,"twenty":-61.462628,"median":-35.44343,"eighty":-3.701581,"marketCap":257766476},{"date":"2025-04-11","current":-3.194007,"twenty":-61.271189,"median":-31.04035,"eighty":-3.397655,"marketCap":229323279},{"date":"2025-04-17","current":-3.707771,"twenty":-61.249311,"median":-18.610536,"eighty":-3.429843,"marketCap":266210551},{"date":"2025-04-25","current":-3.998698,"twenty":-60.904722,"median":-17.913153,"eighty":-3.49979,"marketCap":287098524},{"date":"2025-05-02","current":-4.419614,"twenty":-60.313998,"median":-17.530277,"eighty":-3.557975,"marketCap":317319421},{"date":"2025-05-09","current":-4.302005,"twenty":-59.827198,"median":-17.393535,"eighty":-3.586448,"marketCap":308875347},{"date":"2025-05-16","current":-5.700187,"twenty":-58.946582,"median":-17.1474,"eighty":-3.607494,"marketCap":450930380},{"date":"2025-05-23","current":-5.339701,"twenty":-58.316351,"median":-16.81922,"eighty":-3.64092,"marketCap":422413044},{"date":"2025-05-30","current":-5.553739,"twenty":-57.970542,"median":-16.682479,"eighty":-3.660728,"marketCap":439345212},{"date":"2025-06-06","current":-5.925491,"twenty":-56.891224,"median":-16.203883,"eighty":-3.697867,"marketCap":468753715},{"date":"2025-06-13","current":-5.863532,"twenty":-56.29327,"median":-16.053467,"eighty":-3.717675,"marketCap":463852298},{"date":"2025-06-20","current":-5.908593,"twenty":-55.982023,"median":-15.862029,"eighty":-3.757291,"marketCap":467416965},{"date":"2025-06-27","current":-6.122632,"twenty":-53.001056,"median":-15.383433,"eighty":-3.77586,"marketCap":484349134},{"date":"2025-07-03","current":-6.404261,"twenty":-51.513306,"median":-10.750269,"eighty":-3.795668,"marketCap":506628303},{"date":"2025-07-11","current":-6.578872,"twenty":-50.660039,"median":-6.404261,"eighty":-3.874899,"marketCap":520441387},{"date":"2025-07-18","current":-7.108336,"twenty":-50.32092,"median":-6.590137,"eighty":-3.893469,"marketCap":562326225},{"date":"2025-07-25","current":-7.6378,"twenty":-49.412955,"median":-6.753482,"eighty":-3.9727,"marketCap":604211063},{"date":"2025-08-01","current":-6.990051,"twenty":-48.587036,"median":-6.961888,"eighty":-3.99746,"marketCap":552968974},{"date":"2025-08-08","current":-6.590137,"twenty":-46.8805,"median":-6.764747,"eighty":-3.998698,"marketCap":521332554},{"date":"2025-08-15","current":-5.951139,"twenty":-46.492154,"median":-6.643647,"eighty":-4.11805,"marketCap":520754376},{"date":"2025-08-22","current":-5.961329,"twenty":-46.448396,"median":-6.601402,"eighty":-4.167728,"marketCap":521646079},{"date":"2025-08-29","current":-6.256848,"twenty":-46.3937,"median":-6.581688,"eighty":-4.266238,"marketCap":547505457},{"date":"2025-09-05","current":-7.194356,"twenty":-46.300716,"median":-6.581688,"eighty":-4.297053,"marketCap":629542106},{"date":"2025-09-12","current":-7.34721,"twenty":-46.213201,"median":-6.601402,"eighty":-4.305719,"marketCap":642917646},{"date":"2025-09-19","current":-8.121674,"twenty":-44.993466,"median":-6.643647,"eighty":-4.319893,"marketCap":710687051},{"date":"2025-09-26","current":-8.534381,"twenty":-43.94876,"median":-6.764747,"eighty":-4.33085,"marketCap":746801011},{"date":"2025-10-03","current":-10.266733,"twenty":-43.12831,"median":-6.961888,"eighty":-4.351524,"marketCap":898390470},{"date":"2025-10-10","current":-11.790184,"twenty":-42.592283,"median":-7.068908,"eighty":-4.39733,"marketCap":1031700023},{"date":"2025-10-17","current":-11.497212,"twenty":-40.869338,"median":-7.146788,"eighty":-4.427042,"marketCap":1006063571},{"date":"2025-10-24","current":-11.102338,"twenty":-39.518331,"median":-7.194356,"eighty":-4.55084,"marketCap":971510091},{"date":"2025-10-31","current":-10.949483,"twenty":-39.058879,"median":-7.339567,"eighty":-4.913908,"marketCap":958134551},{"date":"2025-11-07","current":-9.578887,"twenty":-37.155435,"median":-7.357401,"eighty":-5.147066,"marketCap":838200538},{"date":"2025-11-14","current":-14.648361,"twenty":-35.886473,"median":-7.487327,"eighty":-5.196633,"marketCap":861455454},{"date":"2025-11-21","current":-18.097273,"twenty":-35.585642,"median":-7.6378,"eighty":-5.267603,"marketCap":1064282543},{"date":"2025-11-28","current":-22.094357,"twenty":-33.900984,"median":-7.78988,"eighty":-5.319423,"marketCap":1299347051},{"date":"2025-12-05","current":-19.916898,"twenty":-31.401348,"median":-8.060532,"eighty":-5.378003,"marketCap":1171292862},{"date":"2025-12-12","current":-19.954966,"twenty":-31.056759,"median":-8.182815,"eighty":-5.451226,"marketCap":1173531572},{"date":"2025-12-19","current":-20.96756,"twenty":-27.412726,"median":-8.753473,"eighty":-5.501919,"marketCap":1233081247},{"date":"2025-12-26","current":-22.436964,"twenty":-22.503963,"median":-9.413294,"eighty":-5.544727,"marketCap":1319495438},{"date":"2026-01-02","current":-21.226419,"twenty":-22.436964,"median":-9.632386,"eighty":-5.553739,"marketCap":1248304472},{"date":"2026-01-09","current":-19.597131,"twenty":-22.436964,"median":-9.915167,"eighty":-5.569002,"marketCap":1152487702},{"date":"2026-01-16","current":-20.845744,"twenty":-22.436964,"median":-10.381374,"eighty":-5.593168,"marketCap":1225917376},{"date":"2026-01-23","current":-20.305186,"twenty":-22.162878,"median":-10.567347,"eighty":-5.611192,"marketCap":1194127700},{"date":"2026-01-30","current":-18.120114,"twenty":-22.094357,"median":-10.857771,"eighty":-5.615698,"marketCap":1065625769},{"date":"2026-02-06","current":-18.607377,"twenty":-21.850725,"median":-11.071767,"eighty":-5.615698,"marketCap":1094281252},{"date":"2026-02-13","current":-19.612358,"twenty":-21.722819,"median":-11.209336,"eighty":-5.64356,"marketCap":1153383185},{"date":"2026-02-20","current":-20.61734,"twenty":-21.739568,"median":-11.372381,"eighty":-5.676942,"marketCap":1212485119},{"date":"2026-02-27","current":-23.053657,"twenty":-22.094357,"median":-11.478105,"eighty":-5.697934,"marketCap":1355762533},{"date":"2026-03-06","current":-20.914266,"twenty":-22.094357,"median":-11.754518,"eighty":-5.704017,"marketCap":1229947054},{"date":"2026-03-13","current":-24.295691,"twenty":-22.288862,"median":-11.879349,"eighty":-5.719638,"marketCap":1187549060},{"date":"2026-03-20","current":-22.30665,"twenty":-22.436964,"median":-13.780423,"eighty":-5.741868,"marketCap":1090326760},{"date":"2026-03-27","current":-22.729264,"twenty":-22.436964,"median":-14.644554,"eighty":-5.761019,"marketCap":1110983692},{"date":"2026-04-02","current":-22.389336,"twenty":-22.436964,"median":-14.872318,"eighty":-5.77679,"marketCap":1094368334},{"date":"2026-04-10","current":-22.811949,"twenty":-22.645844,"median":-15.588546,"eighty":-5.790308,"marketCap":1115025266},{"date":"2026-04-17","current":-22.958945,"twenty":-22.751313,"median":-15.862029,"eighty":-5.81451,"marketCap":1122210286},{"date":"2026-04-24","current":-22.940571,"twenty":-22.897489,"median":-16.108164,"eighty":-5.8559,"marketCap":1121312158},{"date":"2026-05-01","current":-21.828913,"twenty":-22.897489,"median":-16.346578,"eighty":-5.87705,"marketCap":1066975446},{"date":"2026-05-08","current":-22.031033,"twenty":-22.828174,"median":-16.573085,"eighty":-5.90051,"marketCap":1076854848},{"date":"2026-05-15","current":-35.420064,"twenty":-23.014069,"median":-16.805546,"eighty":-5.906606,"marketCap":1276539094},{"date":"2026-05-22","current":-34.91978,"twenty":-23.096754,"median":-17.065355,"eighty":-5.913099,"marketCap":1258508881},{"date":"2026-05-29","current":-38.834498,"twenty":-23.422893,"median":-17.338839,"eighty":-5.920985,"marketCap":1399595299},{"date":"2026-06-05","current":-39.234724,"twenty":-23.969543,"median":-17.448232,"eighty":-5.926617,"marketCap":1414019470},{"date":"2026-06-12","current":-42.561609,"twenty":-25.529539,"median":-17.587169,"eighty":-5.93225,"marketCap":1533920387},{"date":"2026-06-18","current":-44.775363,"twenty":-30.958305,"median":-17.712792,"eighty":-5.936756,"marketCap":1613704081},{"date":"2026-06-26","current":-43.19947,"twenty":-32.893633,"median":-17.963339,"eighty":-5.951139,"marketCap":1556908909},{"date":"2026-07-02","current":-43.28702,"twenty":-34.942293,"median":-18.108694,"eighty":-5.953151,"marketCap":1560064197},{"date":"2026-07-10","current":-47.326808,"twenty":-35.535865,"median":-18.432772,"eighty":-5.955718,"marketCap":1705658168},{"date":"2026-07-17","current":-39.472359,"twenty":-37.456217,"median":-18.865336,"eighty":-5.96031,"marketCap":1422583821},{"date":"2026-07-24","current":-41.861212,"twenty":-38.129098,"median":-19.056573,"eighty":-5.968707,"marketCap":1508678089},{"date":"2026-07-31","current":-43.999924,"twenty":-38.804481,"median":-19.345886,"eighty":-5.971132,"marketCap":1585757250},{"date":"2026-08-07","current":-49.440506,"twenty":-39.282531,"median":-19.37634,"eighty":-6.008114,"marketCap":1781835819},{"date":"2026-08-14","current":-86.93668,"twenty":-40.880657,"median":-19.444862,"eighty":-6.039269,"marketCap":2106997387},{"date":"2026-08-21","current":-78.558866,"twenty":-41.886226,"median":-19.559064,"eighty":-6.073792,"marketCap":1903952668}],"updateTime":1787524699809},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SEPN\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618674208","title":"Biotech firm Septerna beats Q4 revenue expectations, net loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2618674208","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618674208?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:22","pubTimestamp":1773087779,"startTime":"0","endTime":"0","summary":"Biotech firm Septerna beats Q4 revenue expectations, net loss narrowsOverviewBiotechnology firm's Q4 revenue beat analyst expectationsCompany reported net loss of $10.7 mln for Q4, down from $20.7 mln","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL1N3ZX14H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618747626","title":"Earnings Flash (SEPN) Septerna Posts Q4 Loss $-0.24, vs. FactSet Est of Loss of $-0.24","url":"https://stock-news.laohu8.com/highlight/detail?id=2618747626","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618747626?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:22","pubTimestamp":1773087766,"startTime":"0","endTime":"0","summary":"Earnings Flash (SEPN) Septerna Posts Q4 Loss $-0.24, vs. FactSet Est of Loss of $-0.24","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618674991","title":"Septerna Q4 EPS $(0.24) Misses $0.03 Estimate, Sales $24.118M Miss $32.667M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2618674991","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618674991?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:14","pubTimestamp":1773087265,"startTime":"0","endTime":"0","summary":"Septerna (NASDAQ:SEPN) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $0.03 by 988.89 percent. This is a 62.5 percent increase over losses of $(0.64) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51143450/septerna-q4-eps-0-24-misses-0-03-estimate-sales-24-118m-miss-32-667m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Septerna Q4 EPS $(0.24) Misses $0.03 Estimate, Sales $24.118M Miss $32.667M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618674890","title":"Septerna Q4 revenue hits USD 24.12 million as net loss narrows 48% to USD 10.74 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618674890","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618674890?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:05","pubTimestamp":1773086746,"startTime":"0","endTime":"0","summary":"Septerna reported Q4 revenue of USD 24.12 million and a Q4 net loss of USD 10.74 million. R&D expenses rose 65% to USD 31.86 million, while G&A expenses increased 48% to USD 8.28 million. For FY 2025, revenue was USD 45.95 million and net loss was USD 48.88 million. FY R&D expenses increased 49% to USD 97.58 million and FY G&A expenses rose 76% to USD 29.16 million. Cash, cash equivalents and marketable securities totaled USD 548.66 million at year-end, and management said its cash runway is expected to fund operations at least into 2029.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL5WcZ2s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4588","IE00BGHQF748.EUR","BK4007","IE00B64PRP62.GBP","NDAQ","BK4585","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","SEPN","SG9999014013.SGD","SG9999014021.USD","SG9999014039.USD","LU2210150020.SGD","BK4112","LU2210149790.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618671005","title":"Septerna Inc Q4 Income From Operations USD -16.023 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618671005","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618671005?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:05","pubTimestamp":1773086702,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nPLX564560:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SEPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618390674","title":"Press Release: Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618390674","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618390674?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:05","pubTimestamp":1773086700,"startTime":"0","endTime":"0","summary":"Compelling Phase 1 Data for SEP-631  in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria  in Second Half of 2026. Advancing SEP-479  Toward Phase 1 Initiation in First Half of 2026. Cash Runway Expected to Support Operating Plans at Least into 2029. SOUTH SAN FRANCISCO, Calif., March 09, 2026  -- Septerna, Inc. , a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor  drug discovery, today highlighted pipeline progress and anticipated milestones and reported financial results for the fourth quarter and full year ended December 31, 2025.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4097","BK4599","LU1169589451.USD","SEPN","LU1169590202.USD","PRGS","LU2065732104.USD","BK4218","BK4023","BK4181","GPCR","PK","PD","R","BK4007","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617560051","title":"Septerna Chief People Officer Samira Shaikhly Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2617560051","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617560051?lang=en_us&edition=fundamental","pubTime":"2026-03-05 08:01","pubTimestamp":1772668885,"startTime":"0","endTime":"0","summary":"Samira Shaikhly, Chief People Officer of Septerna Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Septerna Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL8YQjgG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Septerna Chief People Officer Samira Shaikhly Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616321752","title":"Septerna Is Maintained at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2616321752","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616321752?lang=en_us&edition=fundamental","pubTime":"2026-03-03 23:18","pubTimestamp":1772551080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SEPN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2026 10:18 ET (15:18 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616340224","title":"Septerna (SEPN): Early Proof-of-Concept for SEP-631 in Mast Cell–Driven Disease Supports Long-Term Growth Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2616340224","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616340224?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:55","pubTimestamp":1772542530,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Tessa Romero has maintained their bullish stance on SEPN stock, giving a Buy rating yesterday. Tessa Romero’s rating is based o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/septerna-sepn-early-proof-of-concept-for-sep-631-in-mast-cell-driven-disease-supports-long-term-growth-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/septerna-sepn-early-proof-of-concept-for-sep-631-in-mast-cell-driven-disease-supports-long-term-growth-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1791710582.SGD","LU0795875169.SGD","LU1074936037.SGD","LU0098860793.USD","LU0557290698.USD","LU2271345857.HKD","BK4127","BK4007","LU1548497426.USD","LU0225283273.USD","LU0528227936.USD","BK4588","LU1732800096.USD","LU0267386448.USD","LU2347655156.SGD","BK4516","LU0106831901.USD","LU0158827781.USD","LU1732799900.SGD","LU1244550577.SGD","LU1668664300.SGD","LU0882574139.USD","LU1363072403.SGD","LU2111349929.HKD","LU2089283258.USD","BK4534","LU2133065610.SGD","LU0912757837.SGD","IE00BZ1G4Q59.USD","BK4581","IE00BKVL7J92.USD","LU1989772840.SGD","LU2028103732.USD","LU1989772923.USD","LU1791710400.SGD","LU0795875086.SGD","LU0006306889.USD","SEPN","LU1162221912.USD","LU1244550494.USD","LU0234570918.USD","LU0158827948.USD","LU0320765646.SGD","LU2023251221.USD","LU1244550221.USD","LU1720051017.SGD","LU2357305700.SGD","BK4585","LU0106261372.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616534708","title":"Wells Fargo Sticks to Its Buy Rating for Septerna, Inc. (SEPN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616534708","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616534708?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:37","pubTimestamp":1772541477,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst maintained a Buy rating on Septerna, Inc. today and set a price target of $48.00. The word on The Street in general, suggests a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-its-buy-rating-for-septerna-inc-sepn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-its-buy-rating-for-septerna-inc-sepn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616251357","title":"Septerna Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2616251357","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616251357?lang=en_us&edition=fundamental","pubTime":"2026-03-03 01:56","pubTimestamp":1772474160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SEPN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 12:56 ET (17:56 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616350268","title":"A Look At Septerna (SEPN) Valuation After Recent Share Price Momentum And GPCR Pipeline Reassessment","url":"https://stock-news.laohu8.com/highlight/detail?id=2616350268","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616350268?lang=en_us&edition=fundamental","pubTime":"2026-03-03 01:25","pubTimestamp":1772472338,"startTime":"0","endTime":"0","summary":"Septerna stock: recent moves and what they might mean for investors\nSepterna (SEPN) has attracted attention after a month return of about 24% and a past 3 months return above 10%, prompting investors to reassess how its clinical-stage biotech profile aligns with this recent share performance.\nSee our latest analysis for Septerna.\nThe recent 24.3% 1 month share price return, alongside a 10.9% 3 month share price return and a very large 1 year total shareholder return, suggests momentum has...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sepn/septerna/news/a-look-at-septerna-sepn-valuation-after-recent-share-price-m","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sepn/septerna/news/a-look-at-septerna-sepn-valuation-after-recent-share-price-m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GPCR","BK4599","BK4007","SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616356716","title":"Septerna price target raised to $40 from $35 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2616356716","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616356716?lang=en_us&edition=fundamental","pubTime":"2026-03-02 23:10","pubTimestamp":1772464209,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Septerna (SEPN) to $40 from $35 and keeps a Buy rating on the shares after the company presented ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/septerna-price-target-raised-to-40-from-35-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/septerna-price-target-raised-to-40-from-35-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616565253","title":"Septerna, Inc. : H.c. Wainwright Raises Target Price to $40 From $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2616565253","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616565253?lang=en_us&edition=fundamental","pubTime":"2026-03-02 23:08","pubTimestamp":1772464103,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nAZN4SJ4I4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SEPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616087878","title":"Septerna announces results from Phase 1 trial of SEP-631","url":"https://stock-news.laohu8.com/highlight/detail?id=2616087878","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616087878?lang=en_us&edition=fundamental","pubTime":"2026-03-02 00:30","pubTimestamp":1772382607,"startTime":"0","endTime":"0","summary":"Septerna (SEPN) announced positive results from its Phase 1 clinical trial evaluating SEP-631, a potent and selective oral negative allosteric modu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/septerna-announces-results-from-phase-1-trial-of-sep-631-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/septerna-announces-results-from-phase-1-trial-of-sep-631-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616198820","title":"BRIEF-Septerna Says SEP-631 Well-Tolerated With Adverse Event Profile Comparable To Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2616198820","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616198820?lang=en_us&edition=fundamental","pubTime":"2026-03-01 22:47","pubTimestamp":1772376454,"startTime":"0","endTime":"0","summary":"BRIEF-Septerna Says SEP-631 Well-Tolerated With Adverse Event Profile Comparable To PlaceboMarch 1 (Reuters) - Septerna Inc SEPN.O:SEPTERNA ANNOUNCES POSITIVE PHASE 1 DATA FOR SEP-631, AN ORAL MRGPRX2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260301:nTUACG1DFJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SEPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616820195","title":"Septerna Reports Positive Phase 1 Data for SEP-631 in Mast Cell-Driven Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2616820195","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616820195?lang=en_us&edition=fundamental","pubTime":"2026-03-01 22:45","pubTimestamp":1772376318,"startTime":"0","endTime":"0","summary":"Septerna Inc. reported positive Phase 1 results from a randomized, double-blind, placebo-controlled trial of SEP-631, an oral negative allosteric modulator of MRGPRX2 being developed for mast cell-driven diseases. The company said SEP-631 was well tolerated with an adverse event profile comparable to placebo and showed dose-dependent inhibition of icatibant-induced skin wheal formation, including complete inhibition at doses as low as 10 mg once daily under a 10 g/mL icatibant challenge. Septerna plans to initiate a global randomized, double-blind, placebo-controlled Phase 2b study in adults with moderate-to-severe chronic spontaneous urticaria in the second half of 2026, and later pursue an open-label study in chronic inducible urticaria . The Phase 1 results and Phase 2 strategy will be presented on a company conference call and webcast scheduled for March 2, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260301:nNDL1lqhfq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014005.SGD","SEPN","BK4585","LU2095319765.USD","LU0314104364.USD","LU2210150020.SGD","BK4007","SG9999014013.SGD","IE00B3QW5Z07.USD","BK4588","SG9999014039.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616820166","title":"Septerna Inc - Phase 2 Development for Chronic Spontaneous Urticaria Planned for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2616820166","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616820166?lang=en_us&edition=fundamental","pubTime":"2026-03-01 22:45","pubTimestamp":1772376300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260301:nTUACG1DFJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SEPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616209738","title":"Septerna Announces Positive Phase 1 Data for SEP-631, an Oral Mrgprx2 Nam for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2616209738","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616209738?lang=en_us&edition=fundamental","pubTime":"2026-03-01 22:45","pubTimestamp":1772376300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260301:nTUACG1DFJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SEPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616163820","title":"Septerna Inc - SEP-631 Well-Tolerated With Adverse Event Profile Comparable to Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2616163820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616163820?lang=en_us&edition=fundamental","pubTime":"2026-03-01 22:45","pubTimestamp":1772376300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260301:nTUACG1DFJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SEPN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":103,"code":"91000000","status":"200"}]}}